Evidence map›Paper›PMID 27539931›Full record

ReviewJournal of psychopharmacology (Oxford, England)2016

Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next.

Neal R Swerdlow, David L Braff, Mark A Geyer

Open access · greenAbstract readReview
In one paragraph

Review in Journal of psychopharmacology (Oxford, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 4 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 4 syntheses or guidelines pooled it, 187 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Effect of Traumatic Brain Injury on Sensorimotor Gating.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Affective phenotypes in heterozygousFrontiers in genetics · 2025
    Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Neal R SwerdlowDepartment of Psychiatry, University of California San Diego School of Medicine, La Jolla, CA, USA nswerdlow@ucsd.edu.
David L BraffDepartment of Psychiatry, University of California San Diego School of Medicine, La Jolla, CA, USA.
Mark A GeyerDepartment of Psychiatry, University of California San Diego School of Medicine, La Jolla, CA, USA.
University of California, San Diego · US

Funding

The Genetics of Endophenotypes and SchizophreniaR01MH065571 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRAFF, DAVID L. · 2003 to 2013
$7.0M
SENSORY GATING &HABITUATION IN SCHIZOPHRENIAR01MH042228 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRAFF, DAVID L. · 1987 to 2015
$6.5M
Pharmacologic augmentation of neurocognition and cognitive training in psychosisR01MH059803 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 1999 to 2018
$4.5M
Inhibitory Deficits in Mania and Hyperdopaminiergic MiceR01MH071916 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GEYER, MARK A, PERRY, WILLIAM · 2004 to 2014
$4.2M
Memantine effects on sensorimotor gating and neurocognition in schizophreniaR01MH094320 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 2012 to 2020
$2.6M
SENSORY GATING AND HABITUATION IN SCHIZOPHRENIAR37MH042228 · NIMH · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI BRAFF, DAVID L. · 1993 to 2002
$1.3M
Biomarker Strategies for Medication-Enhanced Cognitive Training in SchizophreniaR34MH093453 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 2011 to 2013
$689k
NIMH NIH HHS R01 MH042228NIMH NIH HHS R01 MH059803NIMH NIH HHS R01 MH065571NIMH NIH HHS R01 MH071916NIMH NIH HHS R01 MH094320NIMH NIH HHS R34 MH093453NIMH NIH HHS R37 MH042228
6 · The paper itself

Abstract

Our 1992 paper, 'The neural substrates of sensorimotor gating of the startle reflex: a review of recent findings and their implications', reviewed a series of (then) new and preliminary findings from cross-species studies of prepulse inhibition of the startle reflex, and commented on their implications. At the time that the report was composed, PubMed listed about 40 citations for studies using the search term 'prepulse inhibition'. In the ensuing 25 years, the field has added about 2700 such reports, reflecting the substantial growth in interest in prepulse inhibition and its utility across a number of different experimental applications. The 30th anniversary of the Journal of Psychopharmacology provides an opportunity to comment briefly on what was described in that 1992 report, how the field has progressed in the subsequent decades, and the paths forward for studies of prepulse inhibition and its use as an operational measure of sensorimotor gating. Among these future paths, we highlight the use of prepulse inhibition as: an endophenotype for genomic studies, and a biomarker for healthy brain circuitry, which may predict sensitivity to psychotherapeutics. Our 1992 report was highly speculative and based on paper-thin empirical data, yet viewed in a certain light, it appears to have contained a basic roadmap for a journey spanning the next 25 years of prepulse inhibition research… and 'what a long, strange trip it's been'.

Indexed as

AnimalsBiomarkersBrainHumansPrepulse InhibitionPsychotropic DrugsReflex, StartleSensory GatingBiomarkersPsychotropic DrugsAntipsychoticdopamineprepulse inhibitionschizophreniasensorimotor gatingstartle reflex

Identifiers

PMID27539931
PMCPMC6036900
OpenAlexW2510669443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.